Cerasuolo Damiano, Tejeda-Reyes Darbelis, Couchoud Cécile, Guerrot Dominique, Touré-Diabira Fatouma, Vacher-Coponat Henri, Lobbedez Thierry, Morello Rémy, Béchade Clémence, Guittet Lydia
Biostatistics and Clinical Research Unit, Caen-Normandy University Hospital, Caen, France.
ANTICIPE U1086 INSERM, University of Caen Normandy Centre Hospitalier Universitaire de Caen Bâtiment Biologie, Recherche Avenue de la Côte de Nacre CS 30001, 14033, Caen Cedex 9, France.
Clin Kidney J. 2025 Feb 19;18(4):sfaf028. doi: 10.1093/ckj/sfaf028. eCollection 2025 Apr.
The risk of ischaemic or haemorrhagic strokes in patients living with end-stage renal disease and receiving replacement therapy is more than double that of non-dialysed individuals. Autosomal dominant polycystic kidney disease (ADPKD) is an inherited systemic disorder associated with renal and non-renal manifestations, including intracerebral aneurysms. The role of underlying nephropathy in determining the onset of the stroke is unclear.
All patients who started dialysis between 1 January 2015 and 31 December 2019 were included in the analysis. Data were retrieved from the REIN registry and the French national Health Data System (SNDS). Cases of stroke were extracted from the SNDS by using ICD-10 codes. The first stroke observed during the follow-up, irrespective of its nature, was considered as the event of the main analysis, based on a semi-parametric survival model.
The analysis included 40 980 patients on dialysis. Overall, 1549 patients experienced stroke during the follow-up. The first stroke was ischaemic in 1148 (74.1%) and haemorrhagic in the remaining 281 patients. The cumulative incidence of stroke on dialysis was 1.58 per 100 person-years (95% CI = 1.51, 1.70). Among 2182 ADPKD patients, only 44 (2%) experienced stroke. ADPKD was not significantly associated with an increased risk of all types of stroke, after considering major risk factors.
We found no increase in the risk of stroke in ADPKD patients under dialysis. We believe that the findings of our study support a similar screening strategy in ADPKD patients on dialysis compared with patients not on dialysis.
终末期肾病患者接受替代治疗时发生缺血性或出血性卒中的风险是非透析患者的两倍多。常染色体显性遗传性多囊肾病(ADPKD)是一种遗传性全身性疾病,与肾脏及非肾脏表现相关,包括颅内动脉瘤。潜在肾病在卒中发病中的作用尚不清楚。
纳入2015年1月1日至2019年12月31日期间开始透析的所有患者进行分析。数据取自REIN登记处和法国国家卫生数据系统(SNDS)。通过使用国际疾病分类第十版(ICD - 10)编码从SNDS中提取卒中病例。基于半参数生存模型,随访期间观察到的首次卒中,无论其性质如何,均被视为主要分析事件。
分析纳入了40980例透析患者。总体而言,1549例患者在随访期间发生卒中。首次卒中为缺血性的有1148例(74.1%),其余281例为出血性。透析患者卒中的累积发病率为每100人年1.58例(95%置信区间 = 1.51, 1.70)。在2182例ADPKD患者中,只有44例(2%)发生卒中。在考虑主要危险因素后,ADPKD与各类卒中风险增加无显著相关性。
我们发现透析的ADPKD患者卒中风险没有增加。我们认为本研究结果支持对透析的ADPKD患者采用与未透析患者类似的筛查策略。